Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2021 > Center for Cancer Genomics and Advanced Therapeutics

Annual Report 2021

Liaison for Cancer Genomic Medicine Hospitals Section

Tatsuya Suzuki, Natsuko Okita, Hideki Ueno, Yusuke Okuma

Introduction

 Our mission in this liaison office is to promote cancer genomic medicine by sharing and solving practical problems of the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) among the staff at Cancer Genomic Medicine Hospitals.

 Cancer genomic medicine requires enrichment of human resources, systems, know-how in operations, and the realization of different needs according to each region. Our aim is to capture and share these needs, issues, and practical know-how, so that cancer genomic medicine is performed in a cooperative and efficient manner, and at the same time ensure safety for patients.

 We periodically hold online meetings with members of the Designated Core Hospitals for Cancer Genomics Medicine nationwide to share issues and come up with solutions.

The Team and What We Do

 Our team monitors advanced therapeutics in relation to panel genetic tests, serves as secretariat to the clinical working group of the General Assembly of the Designated Core Hospitals for Cancer Genomic Medicine, and promotes collaboration with Designated Core Hospitals for Cancer Genomic Medicine.

Research activities

 The activities of the clinical working group were presented at the 2022 Japanese Society of Medical Oncology Annual Meeting.